No abstract

Idiopathic pulmonary fibrosis is one of the most common entities of the family of disorders known as the interstitial lung diseases. It is a chronic, progressive, and often-fatal disease with a median survival time of 3 to 5 years. In 2014 the US Food and Drug Administration approved pirfenidone and nintedanib, two antifibrotic agents for the treatment of idiopathic pulmonary fibrosis. Because these are the only drugs approved that can alter the course of this rare but fatal disease, this article reviews the major studies that led to the approval of these drugs and examines the indications for treatment and the expected outcomes of therapy.

Receiving any component of a post-discharge integrated disease management program was associated with reduced 90-d readmission rate. Previous health-care utilization and lung function impairment were strong predictors of readmission.

The Management of fluid in the post-operative period following lung transplantation is very delicate as there is need to maintain adequate filling pressures and cardiac output while minimizing the risk of developing pulmonary edema and reperfusion injury. The purpose of the study is to evaluate the impact of post-operative fluid status on lung transplant outcomes. METHODS: A retrospective single center cohort analysis was done on 123 charts of patients that underwent a lung transplant between February 4, 2013 and through November 1, 2018 at Spectrum Health Butterworth. Logistic regression was used to determine if fluid balance at 72 hours was associated with development of PGD in lung transplant patients. The secondary outcomes analyzed were need for vasodilators at 7 days; ICU length of stay; AKI within 30 days of discharge; need for continuous renal replacement therapy (CRRT) and need for re-admission within 30 days of discharge.

No abstract